Hospital Universitario Son Espases<\/a> ha participado en la publicaci\u00f3n de los datos del mundo real de la monoterapia de primera l\u00ednea con cemiplimab para el c\u00e1ncer de pulm\u00f3n no microc\u00edtico (NSCLC) metast\u00e1sico con expresi\u00f3n de PD-L1 \u2265 50%.<\/p>","protected":false},"excerpt":{"rendered":"Oncolog\u00eda del Hospital Universitario Son Espases ha participado en la publicaci\u00f3n de los datos del mundo real de la monoterapia de primera l\u00ednea con cemiplimab para el c\u00e1ncer de pulm\u00f3n no microc\u00edtico (NSCLC) metast\u00e1sico con expresi\u00f3n de PD-L1 \u2265 50%.<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[5],"tags":[],"class_list":["post-199660","post","type-post","status-publish","format-standard","hentry","category-noticias"],"yoast_head":"\n
Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50% - bip4ex<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-\u2265-50\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%\" \/>\n<meta property=\"og:description\" content=\"Oncolog\u00eda del Hospital Universitario Son Espases ha participado en la publicaci\u00f3n de los datos del mundo real de la monoterapia de primera l\u00ednea con cemiplimab para el c\u00e1ncer de pulm\u00f3n no microc\u00edtico (NSCLC) metast\u00e1sico con expresi\u00f3n de PD-L1 \u2265 50%.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-\u2265-50\/\" \/>\n<meta property=\"og:site_name\" content=\"bip4ex\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T07:17:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg\" \/>\n<meta name=\"author\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Luis Miguel Mej\u00edas Ramos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/\"},\"author\":{\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\"},\"headline\":\"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%\",\"datePublished\":\"2026-03-03T07:17:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/\"},\"wordCount\":59,\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1586.jpg\",\"articleSection\":[\"Noticias\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/\",\"name\":\"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50% - bip4ex\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1586.jpg\",\"datePublished\":\"2026-03-03T07:17:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1586.jpg\",\"contentUrl\":\"https:\\\/\\\/www.infosalut.com\\\/images\\\/noticies\\\/infosalut\\\/epr1586.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#website\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"name\":\"bip4ex\",\"description\":\"Vigilancia Tecnol\u00f3gica\",\"publisher\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#organization\",\"name\":\"Helloproject.es\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"contentUrl\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/wp-content\\\/uploads\\\/2023\\\/07\\\/bip4ex.png\",\"width\":322,\"height\":365,\"caption\":\"Helloproject.es\"},\"image\":{\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/#\\\/schema\\\/person\\\/3767b0619d59a11570372c821f8619ca\",\"name\":\"Luis Miguel Mej\u00edas Ramos\",\"url\":\"https:\\\/\\\/helloproject.es\\\/vigilancia\\\/author\\\/luismi\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50% - bip4ex","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-\u2265-50\/","og_locale":"es_ES","og_type":"article","og_title":"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%","og_description":"Oncolog\u00eda del Hospital Universitario Son Espases ha participado en la publicaci\u00f3n de los datos del mundo real de la monoterapia de primera l\u00ednea con cemiplimab para el c\u00e1ncer de pulm\u00f3n no microc\u00edtico (NSCLC) metast\u00e1sico con expresi\u00f3n de PD-L1 \u2265 50%.","og_url":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-\u2265-50\/","og_site_name":"bip4ex","article_published_time":"2026-03-03T07:17:19+00:00","og_image":[{"url":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg","type":"","width":"","height":""}],"author":"Luis Miguel Mej\u00edas Ramos","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Luis Miguel Mej\u00edas Ramos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#article","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/"},"author":{"name":"Luis Miguel Mej\u00edas Ramos","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca"},"headline":"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%","datePublished":"2026-03-03T07:17:19+00:00","mainEntityOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/"},"wordCount":59,"publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg","articleSection":["Noticias"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/","url":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/","name":"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50% - bip4ex","isPartOf":{"@id":"https:\/\/helloproject.es\/vigilancia\/#website"},"primaryImageOfPage":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#primaryimage"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#primaryimage"},"thumbnailUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg","datePublished":"2026-03-03T07:17:19+00:00","breadcrumb":{"@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#primaryimage","url":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg","contentUrl":"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/helloproject.es\/vigilancia\/cemiplimab-en-monoterapia-de-primera-linea-para-el-nsclc-metastatico-pd-l1-%e2%89%a5-50\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/helloproject.es\/vigilancia\/"},{"@type":"ListItem","position":2,"name":"Cemiplimab en monoterapia de primera l\u00ednea para el NSCLC metast\u00e1tico PD-L1 \u2265 50%"}]},{"@type":"WebSite","@id":"https:\/\/helloproject.es\/vigilancia\/#website","url":"https:\/\/helloproject.es\/vigilancia\/","name":"bip4ex","description":"Vigilancia Tecnol\u00f3gica","publisher":{"@id":"https:\/\/helloproject.es\/vigilancia\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/helloproject.es\/vigilancia\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/helloproject.es\/vigilancia\/#organization","name":"Helloproject.es","url":"https:\/\/helloproject.es\/vigilancia\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/","url":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","contentUrl":"https:\/\/helloproject.es\/vigilancia\/wp-content\/uploads\/2023\/07\/bip4ex.png","width":322,"height":365,"caption":"Helloproject.es"},"image":{"@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/helloproject.es\/vigilancia\/#\/schema\/person\/3767b0619d59a11570372c821f8619ca","name":"Luis Miguel Mej\u00edas Ramos","url":"https:\/\/helloproject.es\/vigilancia\/author\/luismi\/"}]}},"_links":{"self":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/199660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/comments?post=199660"}],"version-history":[{"count":0,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/posts\/199660\/revisions"}],"wp:attachment":[{"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/media?parent=199660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/categories?post=199660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/helloproject.es\/vigilancia\/wp-json\/wp\/v2\/tags?post=199660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/www.infosalut.com\/images\/noticies\/infosalut\/epr1586.jpg\")
<\/p>\n